| Nov 12 |
Ultragenyx: Ready For More Growth After Q3 Earnings Beat
|
| Nov 9 |
Ultragenyx posts trial data backing Phase 3 design for Angelman syndrome therapy
|
| Nov 9 |
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
|
| Nov 7 |
Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 6 |
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates
|
| Nov 6 |
Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts
|
| Nov 6 |
Ultragenyx: Excellent Company, Lackluster Stock
|
| Nov 6 |
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ...
|
| Nov 6 |
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript
|
| Nov 5 |
Ultragenyx Pharmaceutical Inc. 2024 Q3 - Results - Earnings Call Presentation
|
